Funding Announcement

OpenEvidence, a technology company that markets an AI‑driven platform often described as "ChatGPT for medicine," announced a new financing round of $200 million. The infusion of capital brings the company’s valuation to $6 billion, according to the report. This round arrives just three months after the startup closed a $210 million round that valued it at $3.5 billion, underscoring strong investor appetite for specialized artificial‑intelligence solutions in health care.

Company Background

Founded in 2022, OpenEvidence has positioned itself at the intersection of large‑language‑model technology and clinical knowledge. The platform is trained on reputable medical publications, including the Journal of the American Medical Association (JAMA) and the New England Journal of Medicine (NEJM). By leveraging this curated data, the service helps health‑care professionals quickly retrieve answers to existing medical knowledge, supporting patient treatment decisions.

Product and Market Position

OpenEvidence offers its tool to verified medical professionals at no cost, with the service funded through advertising. The model aims to provide clinicians with fast, reliable information without the need for a paid subscription, differentiating it from other AI offerings that rely on direct user fees. The platform’s focus on evidence‑based answers aligns with the growing demand for trustworthy AI assistance in clinical settings.

Growth Metrics

Since its inception, the company has experienced rapid adoption. Clinical consultations processed by the platform have nearly doubled, reaching approximately 15 million per month as of July. This surge reflects both the expanding user base and the increasing reliance on AI tools for day‑to‑day medical decision‑making.

Investor Participation

The latest financing round was led by Google Ventures. Additional participants include Sequoia Capital, Kleiner Perkins, Blackstone, Thrive Capital, Coatue Management, Bond, and Craft. The involvement of these prominent venture firms highlights confidence in OpenEvidence’s technology and its potential to reshape information access for health‑care providers.

Outlook

With substantial new capital and a valuation that places it among the most valuable AI startups, OpenEvidence is positioned to scale its platform, deepen its data integrations, and expand its user community. Industry observers note that the company’s growth trajectory and investor backing suggest a continued push toward mainstream AI adoption in clinical environments.

Usado: News Factory APP - descubrimiento de noticias y automatización - ChatGPT para Empresas